Efficacy and safety of telaprevir (TVR) triple therapy in a real-life cohort of 102 patients with HCV genotype 1: interim analysis after 24 weeks of treatment
Journal of Viral Hepatitis, 08/15/2013 Werner CR et al.
Since 2011, telaprevir (TVR)–based triple therapy is the new treatment standard for hepatitis C genotype 1 virus infection. The aim of the retrospective interim analysis encompassing the first 24 weeks on TVR–based triple therapy was to assess ‘real–life’ antiviral efficacy and side effects in a large single–centre cohort, both in comparison with the data obtained in large prospective clinical trials. TVR–based triple therapy exhibited a high frequency of side effects requiring multiple therapeutic interventions. Notably, in the ‘real–life’ cohort, no lethal case was observed so far.
In total, the authors treated 102 patients: 24 treatment–naive patients, 58 patients pretreated with PEG–IFN/RBV (thereof: 28 with nonresponse, 25 with relapse, five unknown) and 20 patients who previously had received nonpegylated interferon.
74 of 102 patients were assigned with HCV genotype 1b; 34 of 102 patients were treated in the context of liver cirrhosis.
72 of 102 patients have reached treatment week 24 (mean treatment duration 31 weeks).
In the ITT analysis, overall response rates were at: week 4: 66%; week 12: 85%; and week 24: 78%.
So far, 24 patients discontinued treatment prematurely, of those, 10 patients were due to virological failure.
Haematological side effects were frequent (40% anaemia), as were ‘flu–like’ symptoms (94%), rash (65%) and pruritus (79%).
According to the interim ITT analysis encompassing up to 24 weeks of TVR–based triple therapy, the ‘real–life’ antiviral effects are comparable to the results of large multicentric clinical trials.
MDLinx connects healthcare professionals and patients to tomorrow's important medical news, while providing the pharmaceutical and healthcare industries with highly targeted interactive marketing, education, content, and medical research solutions.